Analytical Data
-
Gene name
KCNQ5
- Application
-
Alternative Names
KCNQ 5; KCNQ5; KCNQ5_HUMAN; KQT like 5 ; KQT-like 5; Kv7.5; OTTHUMP00000064152; OTTHUMP00000064153; Potassium channel alpha subunit KvLQT5; Potassium channel protein; Potassium channel subunit alpha KvLQT5; Potassium voltage gated channel KQT like subfamily member 5; Potassium voltage gated channel subfamily KQT member 5
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NR82
-
Expression Region
1-932aa
-
AA Sequence
MPRHHAGGEEGGAAGLWVKSGAAAAAAGGGRLGSGMKDVESGRGRVLLNSAAARGDGLLLLGTRAATLGGGGGGLRESRRGKQGARMSLLGKPLSYTSSQSCRRNVKYRRVQNYLYNVLERPRGWAFIYHAFVFLLVFGCLILSVFSTIPEHTKLASSCLLILEFVMIVVFGLEFIIRIWSAGCCCRYRGWQGRLRFARKPFCVIDTIVLIASIAVVSAKTQGNIFATSALRSLRFLQILRMVRMDRRGGTWKLLGSVVYAHSKELITAWYIGFLVLIFSSFLVYLVEKDANKEFSTYADALWWGTITLTTIGYGDKTPLTWLGRLLSAGFALLGISFFALPAGILGSGFALKVQEQHRQKHFEKRRNPAANLIQCVWRSYAADEKSVSIATWKPHLKALHTCSPTKKEQGEASSSQKLSFKERVRMASPRGQSIKSRQASVGDRRSPSTDITAEGSPTKVQKSWSFNDRTRFRPSLRLKSSQPKPVIDADTALGTDDVYDEKGCQCDVSVEDLTPPLKTVIRAIRIMKFHVAKRKFKETLRPYDVKDVIEQYSAGHLDMLCRIKSLQTRVDQILGKGQITSDKKSREKITAEHETTDDLSMLGRVVKVEKQVQSIESKLDCLLDIYQQVLRKGSASALALASFQIPPFECEQTSDYQSPVDSKDLSGSAQNSGCLSRSTSANISRGLQFILTPNEFSAQTFYALSPTMHSQATQVPISQSDGSAVAATNTIANQINTAPKPAAPTTLQIPPPLPAIKHLPRPETLHPNPAGLQESISDVTTCLVASKENVQVAQSNLTKDRSMRKSFDMGGETLLSVCPMVPKDLGKSLSVQNLIRSTEELNIQLSGSESSGSRGSQDFYPKWRESKLFITDEEVGPEETETDTFDAAPQPAREAAFASDSLRTGRSRSSQSICKAGESTDALSLPHVKLK
-
Molecular Weight
102 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KCNQ5, a member of the KCNQ gene family, encodes voltage-gated potassium channels that play a critical role in setting the resting membrane potential and regulating neuronal excitability. The study of KCNQ5 has garnered significant attention due to its involvement in various physiological processes and its implications in neurological disorders. Mutations in the KCNQ5 gene have been linked to benign familial neonatal seizures (BFNS) and other forms of epilepsy, highlighting its importance in neuronal function. Research on KCNQ5 recombinant proteins has primarily focused on understanding their biophysical properties, pharmacological profiles, and functional mechanisms. These studies typically involve heterologous expression systems to analyze channel behavior, including activation, inactivation, and ion selectivity. Additionally, KCNQ5 channels are influenced by various modulators, including small molecules and lipids, making them potential therapeutic targets for epilepsy treatment. Recent advancements in structural biology methods, such as cryo-electron microscopy, have enhanced our understanding of the channel's architecture and dynamics. By investigating KCNQ5 recombinant proteins, researchers aim to elucidate the underlying mechanisms of ion channel dysfunctions and develop novel strategies for therapeutic interventions in channelopathies associated with KCNQ5. This research represents a critical step towards harnessing the therapeutic potential of KCNQ5 modulation in managing neurological diseases.
